Cost-Effectiveness Comparison of Salmeterol/Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma

This publication has 17 references indexed in Scilit:

• Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs
  Journal of Allergy and Clinical Immunology, 2002
• Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma
  Annals of Allergy, Asthma & Immunology, 2002
• Psychopathology in Patients with Severe Asthma Is Associated with Increased Health Care Utilization
  American Journal of Respiratory and Critical Care Medicine, 2001
• Cost-Efficacy Analysis of Fluticasone Propionate versus Zafirlukast in Patients with Persistent Asthma
  PharmacoEconomics, 2001
• The health economics of asthma and rhinitis. I. Assessing the economic impact
  Journal of Allergy and Clinical Immunology, 2001
• What is meant by intention to treat analysis? Survey of published randomised controlled trials
  BMJ, 1999
• Forecasted state-specific estimates of self-reported asthma prevalence--United States, 1998.
  1998
• Charge what you will ... reimbursements are shrinking.
  1998
• Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic AsthmaA Multicenter, Randomized, Double-blind Trial
  Archives of internal medicine (1960), 1998
• Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.
  American Journal of Respiratory and Critical Care Medicine, 1995